Filters
Different Janus kinase (JAK) inhibitors exhibit differing degrees of efficacy and tolerability against myelofibrosis, a recent meta-analysis has found. In particular, ruxolitinib appears to be the best choice and is a good option as the reference JAK inhibitor.
Delays in the slow phase of heart rate recovery (HRR) may be an early indicator for the risk of developing metabolic syndrome (MetS), a new study has found.
Alcohol intake appears to be a strong risk factor for cancer, while dairy, fruits and vegetables, and coffee exert protective effects, reveals a recent umbrella review of meta-analyses of observational studies.
